

In the Claims:

Claims 1-60 (Cancelled)

1 61. (Currently Amended) An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) the amino acid sequence of SEQ ID NO:2; and  
(b) an immunogenic polypeptide comprising a fragment sequence of at least 15 contiguous amino acids ~~that matches an aligned contiguous segment~~ of SEQ ID NO:2;

wherein the immunogenic fragment ~~isolated, recombinant polypeptide~~, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the ~~to~~ a polypeptide ~~having the sequence of~~ SEQ ID NO:2.

2 62. (Previously Presented): The isolated, recombinant polypeptide of claim 61, wherein the polypeptide is according to (a).

3 63. (Previously Presented): The isolated, recombinant polypeptide of claim 61, wherein the polypeptide is according to (b).

4 64. (Currently Amended): The isolated, recombinant polypeptide of claim 61, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

5 65. (Previously Presented): The isolated, recombinant polypeptide of claim 61, wherein the isolated polypeptide consists of SEQ ID NO:2.

66. (Previously Presented): A fusion protein comprising the isolated, recombinant polypeptide of Claim 61.

67. (Previously Presented) An immunogenic composition comprising the isolated, recombinant polypeptide of Claim 61 and a pharmaceutically acceptable carrier.

68. (Previously Presented) The immunogenic composition of Claim 67, wherein said immunogenic composition further comprises at least one other *Moraxella catarrhalis* antigen.

69. (New): The isolated, recombinant polypeptide of claim 63, wherein the 15 contiguous amino acids comprise amino acids 790-804 of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

70. (New): The isolated, recombinant polypeptide of claim 64, wherein the 20 contiguous amino acids of SEQ ID NO:2 comprise amino acids 676-691 of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

71. (New): An isolated polypeptide consisting of the amino acid sequence SEQ ID NO:2.